VIRTUAL / AUGMENTED REALITY
OCUTRX TECHNOLOGIES SETS NEW STANDARDS IN AUGMENTED AND MIXED REALITY HEALTHCARE WITH OVER 25 PATENTS
In a significant stride for Augmented Reality ( AR ) and 3D technology , Ocutrx Technologies has announced the allowance of its 26th patent , marking a monumental achievement in the company ' s journey towards pioneering innovation in healthcare , enterprise and military applications . This latest patent underscores the relentless innovation and strategic foresight of co-founders Michael Freeman , J . D and Mitchael Freeman , COO propelling Ocutrx to the forefront of AR and Mixed Reality ( MR ) technologies . Jordan Boss , Chief Product Engineer is likewise named on all of the Ocutrx Patents for his contributions to the art-form .
At the heart of Ocutrx ' s technological advancements are the OcuLenz headset for patients and enterprise and ORLenz the AR / XR headset for surgeons , together with the OR-Bot 3D Surgical Visualisation Theatre . The OcuLenz headset represents a transformative solution for individuals suffering from Advanced Macular Degeneration ( AMD ), significantly enhancing their visual capabilities and quality of life . Meanwhile , the OR-Bot 3D Surgical Visualisation Theatre revolutionises surgical procedures by providing unparalleled precision and outcome improvements , demonstrating Ocutrx ' s direct impact on improving healthcare and surgery .
Daniel Henry , Senior Advisor at RSL Holdings , a company which has brokered large AR patent portfolio ' s , said : " Ocutrx ' s patent portfolio , potentially valued between seventy to eighty million dollars , signifies their formidable stance and commitment to enhancing efficiency and patient care through innovative challenges . Their groundbreaking patents are laying the framework for the future of AR and MR , empowering them to lead and transform technology across essential sectors ."
Reflecting on the company ' s progress , Michael Freeman , Founder , CEO and CTO of Ocutrx Technologies , said : " To get over 25 patents since 2019 is remarkable . The rapid issuance of these patents is yet another indicator of Ocutrx ' s strength in the AR / XR / MR and 3D Visualisation space as an innovator and further enhances Ocutrx leadership position in the AR industry . The 26th patent in our patent portfolio is a new milestone and a testament to our team ' s relentless pursuit of innovation and growing patent value for our shareholders . These patents are not merely patent coverage milestones ; they are keystones for developing solutions that profoundly impact people ' s lives , particularly in healthcare and surgery ." �
58 www . intelligenthealth . tech